Microsecretory adenocarcinoma of the hard palate: A case report of a recently described entity. Issue 10 (20th July 2020)

• Record Type: Journal Article
• Authors: Kawakami, Fumi; Nagao, Toshitaka; Honda, Yumi; Sakata, Junki; Yoshida, Ryoji; Nakayama, Hideki; Inoue, Seijiro; Kitajima, Mika; Ikeda, Osamu; Nakaguro, Masato; Mikami, Yoshiki
• Is Part Of: Pathology international. Volume 70:Issue 10(2020)
• Page Start: 781
• Page End: 785
• Publication Date: 2020-07-20
• Subjects: adenocarcinoma not otherwise specified -- hard palate -- MEF2C -- salivary gland -- SS18; Pathology -- Periodicals; 616.07
• DOI: 10.1111/pin.12987
• Languages: English
• ISSNs: 1320-5463

Abstract

Abstract : We report a case of microsecretory adenocarcinoma of the hard palate. The patient is a 37‐year‐old woman with a 15 mm submucosal tumor, which was incidentally found by her primary care dentist, in her hard palate. Preoperative magnetic resonance imaging revealed a tumor exhibiting high signal on T2‐weighted image, which was gradually enhanced on dynamic study. Histologically, the tumor border was ill‐defined without fibrous capsule and adjoined minor salivary gland with permeative infiltration at the tumor periphery. The tumor comprised intercalated duct‐like cells with polygonal narrow eosinophilic to clear cytoplasm and small, uniform oval nuclei. These cells formed small infiltrative microcysts, tubules and fascicular cords collecting pale basophilic secretions and small vacuoles setting in an abundant fibromyxoid stroma. The tumor cells were positive for CK AE1+AE3, S‐100 protein, and p63, while are completely negative for p40, alpha‐SMA, and calponin. The MEF2C‐SS18 fusion was identified by reverse transcriptase‐polymerase chain reaction followed by Sanger sequencing. The combination of characteristic histology, immunophenotype, and presence of MEF2C‐SS18 fusion indicated the diagnosis of microsecretory adenocarcinoma of the hard palate, an entity described only recently. Post‐operative course was uneventful and there was no evidence of disease at 4 months after surgery.